Answers are grounded in this paper and cite their sources.
Retrospective study shows lower FDG PET SUVmax predicts better stereotactic body radiotherapy response in adrenal metastases, indicating its utility as a predictive metabolic biomarker.
Introduction: Stereotactic body radiotherapy (SBRT) is well established for oligometastatic disease, and it is increasingly used to treat adrenal metastases.Material and methods: In this retrospective study we performed an analysis of 75 metastatic adrenal lesions in 64 patients with oligometastatic disease.According to the fluorodeoxyglucose positron emission tomography/ computed tomography (FDG PET/CT) maximum standardized uptake value (SUV max ) of adrenal metastases, patients were categorized into three groups: low, intermediate, and high SUVmax.Results: For all clinicopathological characteristics we found significant relationships for levels of SUV max and objective response rate (Kendall Tau-c = 0.290; p = 0.017).Patients who responded to SBRT had a significantly lower SUV max value than those who did not respond (7.6 ±2.4 vs. 9.7 ±3.8; p = 0.015).At the appropriate SUV max cut-off values, the biomarker distinguished between patients with and without a response significantly and moderately (area under the curve = 0.670, 95% confidence intervals: 0.540-0.790;p = 0.015).Conclusions: Lower SUVmax is associated with a better response to SBRT in patients whose disease progressed mainly in the adrenal glands.
No takes yet. Share an insight, caveat, or question.
Zhelev et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: